Duramesh is claimed to be the world’s first and only mesh suture. Credit: MSi via BusinessWire.

Mesh Suture, which does business as MSi, has secured 510(k) approval from the US Food and Drug Administration (FDA) for Duramesh, a non-absorbable polypropylene mesh suture for the surgical closure of soft tissues, including muscles, fascia, tendons and ligaments.

Duramesh is claimed to be a first-of-its-kind medical device, which uses the implant incorporation in mesh repair in combination with the placement precision of a suture to repair soft tissues.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

The device is intended to reduce the problem of surgical failure resulting from suture pull-through.

A regular suture’s sharp leading edge can slice through intact tissue, which can lead to dehiscence, hernia formation and even poor tendon function. To resist pull-through, Duramesh’s architecture flattens right at the suture-tissue interface.

The open-walled hollow design of Duramesh also enables tissue ingrowth for implant incorporation without the formation of a capsule.

See Also:

Duramesh was found to have fewer hernias and loose sutures numerically when compared to regular sutures in a porcine study.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

MSi chief medical officer Dr Gregory Dumanian said: “Duramesh offers the perfect combination of strength and simplicity in a surgical repair.

“It combines the handling characteristics of traditional suture with a mesh polyfilament design. We are excited to bring this innovative technology to our surgeon colleagues and to their patients who need it most.

“By designing Duramesh to address the surgical complication of suture pull-through, we expect to see sizeable improvements in patient outcomes.”

The device is currently in clinical use in the EU and UK, following receipt of CE Mark designation in Q2 2021.